Rani Therapeutics Secures $20M Funding at Above-Market Price, Bolstering Finances Amid Delisting Concerns
RANI has more than doubled off its 52-week low of $0.387.
Summary
Rani Therapeutics announced a $20 million registered direct offering, selling shares and pre-funded warrants at $1.07 and $1.0699 respectively, which is above its current stock price of $1.01. This critical capital raise follows the company's recent Nasdaq delisting notice due to its low stock price and a reported decrease in cash and material weakness in internal controls. The financing, led by a sovereign wealth fund, provides essential liquidity to support ongoing operations and address financial challenges. The above-market pricing and institutional investor participation are strong positive signals for the company's outlook.
At the time of this announcement, RANI was trading at $1.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $132.4M. The 52-week trading range was $0.39 to $3.87. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.